540 related articles for article (PubMed ID: 18422482)
1. Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis.
Gross V
Expert Opin Pharmacother; 2008 May; 9(7):1257-65. PubMed ID: 18422482
[TBL] [Abstract][Full Text] [Related]
2. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
[TBL] [Abstract][Full Text] [Related]
3. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.
Gross V; Andus T; Caesar I; Bischoff SC; Lochs H; Tromm A; Schulz HJ; Bär U; Weber A; Gierend M; Ewe K; Schölmerich J
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):905-9. PubMed ID: 8889459
[TBL] [Abstract][Full Text] [Related]
4. Budesonide in the treatment of inflammatory bowel disease.
Silverman J; Otley A
Expert Rev Clin Immunol; 2011 Jul; 7(4):419-28. PubMed ID: 21790284
[TBL] [Abstract][Full Text] [Related]
5. Budesonide modified-release capsules.
Baker DE
Rev Gastroenterol Disord; 2001; 1(3):147-55. PubMed ID: 12120182
[TBL] [Abstract][Full Text] [Related]
6. The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease.
Rutgeerts P
Mediators Inflamm; 1998; 7(3):137-40. PubMed ID: 9705597
[TBL] [Abstract][Full Text] [Related]
7. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis.
Miehlke S; Madisch A; Kupcinskas L; Petrauskas D; Böhm G; Marks HJ; Neumeyer M; Nathan T; Fernández-Bañares F; Greinwald R; Mohrbacher R; Vieth M; Bonderup OK;
Gastroenterology; 2014 May; 146(5):1222-30.e1-2. PubMed ID: 24440672
[TBL] [Abstract][Full Text] [Related]
8. [Locally acting corticosteroids in microscopic colitis: are they the treatment of choice? How should they be used?].
Marín-Jiménez I; Yepes Barreto I
Gastroenterol Hepatol; 2008 Sep; 31 Suppl 3():22-6. PubMed ID: 19087860
[No Abstract] [Full Text] [Related]
9. Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial.
Miehlke S; Madisch A; Bethke B; Morgner A; Kuhlisch E; Henker C; Vogel G; Andersen M; Meier E; Baretton G; Stolte M
Gastroenterology; 2008 Nov; 135(5):1510-6. PubMed ID: 18926826
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis: budesonide treatment for collagenous colitis.
Feyen B; Wall GC; Finnerty EP; DeWitt JE; Reyes RS
Aliment Pharmacol Ther; 2004 Oct; 20(7):745-9. PubMed ID: 15379834
[TBL] [Abstract][Full Text] [Related]
11. Microscopic colitis: an unfamiliar but treatable disease.
van der Wouden EJ; Karrenbeld A; Kleibeuker JH; Dijkstra G
Neth J Med; 2009 Feb; 67(2):41-5. PubMed ID: 19299845
[TBL] [Abstract][Full Text] [Related]
12. Increased transmucosal uptake of E. coli K12 in collagenous colitis persists after budesonide treatment.
Münch A; Söderholm JD; Ost A; Ström M
Am J Gastroenterol; 2009 Mar; 104(3):679-85. PubMed ID: 19209166
[TBL] [Abstract][Full Text] [Related]
13. Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study.
Miehlke S; Madisch A; Karimi D; Wonschik S; Kuhlisch E; Beckmann R; Morgner A; Mueller R; Greinwald R; Seitz G; Baretton G; Stolte M
Gastroenterology; 2009 Jun; 136(7):2092-100. PubMed ID: 19303012
[TBL] [Abstract][Full Text] [Related]
14. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease.
Klotz U; Schwab M
Adv Drug Deliv Rev; 2005 Jan; 57(2):267-79. PubMed ID: 15555742
[TBL] [Abstract][Full Text] [Related]
15. Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Germany Budesonide Study Group.
Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
Z Gastroenterol; 1995 May; 33(5):247-50. PubMed ID: 7610691
[TBL] [Abstract][Full Text] [Related]
16. Budesonide treatment and expression of inducible nitric oxide synthase mRNA in colonic mucosa in collagenous colitis.
Bonderup OK; Hansen JB; Madsen P; Vestergaard V; Fallingborg J; Teglbjaerg PS
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1095-9. PubMed ID: 16957516
[TBL] [Abstract][Full Text] [Related]
17. After budesonide, what next for collagenous colitis?
Pardi DS
Gut; 2009 Jan; 58(1):3-4. PubMed ID: 19091826
[No Abstract] [Full Text] [Related]
18. Lymphocytic colitis and collagenous colitis: a review of clinicopathologic features and immunologic abnormalities.
Mahajan D; Goldblum JR; Xiao SY; Shen B; Liu X
Adv Anat Pathol; 2012 Jan; 19(1):28-38. PubMed ID: 22156832
[TBL] [Abstract][Full Text] [Related]
19. Budesonide for the treatment of collagenous colitis: first results of a pilot trial.
Tromm A; Griga T; Möllmann HW; May B; Müller KM; Fisseler-Eckhoff A
Am J Gastroenterol; 1999 Jul; 94(7):1871-5. PubMed ID: 10406251
[TBL] [Abstract][Full Text] [Related]
20. Oral budesonide in the management of Crohn's disease.
Hofer KN
Ann Pharmacother; 2003 Oct; 37(10):1457-64. PubMed ID: 14519035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
